STOK
Stoke Therapeutics Inc

969
Loading...
Loading...
News
all
press releases
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·10h ago
News Placeholder
More News
News Placeholder
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·7d ago
News Placeholder
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today...
Business Wire·7d ago
News Placeholder
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·8d ago
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug
Investing.com -- Jefferies initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating given a better risk-reward profile ahead of late-stage data for its lead drug candidate targeting Dravet syndrome, a severe and rare form of childhood epilepsy.
investing.com·3mo ago
News Placeholder
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Zacks·5mo ago
News Placeholder
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Zacks·5mo ago

Latest STOK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.